Literature DB >> 27312343

Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.

Vishwajith Sridharan1, Evisa Gjini2, Xiaoyun Liao2, Nicole G Chau3, Robert I Haddad3, Mariano Severgnini4, Peter Hammerman3, Adel El-Naggar5, Gordon J Freeman3, F Stephen Hodi6, Scott J Rodig7, Glenn Dranoff8, Jonathan D Schoenfeld9.   

Abstract

Adenoid cystic carcinoma (ACC) is among the most lethal salivary gland tumors, with no treatments for metastatic disease that prolong survival. We examined tissue from 28 primary and metastatic ACC deposits obtained from 21 patients for infiltrating immune cells and PD-L1/PD-L2 expression and determined mRNA profiles of over 1,400 oncogenic and immune-related genes. We also assessed the effect of chemoradiation on immune mediators in a patient who had serial biopsies available. Most tumors expressed PD-L2 but had few infiltrating immune cells. Lack of immune-cell infiltrate was associated with expression of genes in the β-catenin/Wnt and PI3K pathways. Additionally, certain transcripts linked to growth and invasion were differentially expressed among primary and metastatic deposits. Chemoradiation appeared to increase CD8(+) effector T cells, decrease regulatory T cells, and promote a systemic humoral response. These data suggest a potential role for PD-L2 inhibition and immune modulation as treatment for patients with ACC. Cancer Immunol Res; 4(8); 679-87. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27312343     DOI: 10.1158/2326-6066.CIR-16-0031

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  22 in total

1.  Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues.

Authors:  Noah Sorrelle; Debolina Ganguly; Adrian T A Dominguez; Yuqing Zhang; Huocong Huang; Lekh N Dahal; Natalie Burton; Arturas Ziemys; Rolf A Brekken
Journal:  J Immunol       Date:  2018-12-03       Impact factor: 5.422

Review 2.  Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments.

Authors:  Luana Guimaraes de Sousa; Katarina Jovanovic; Renata Ferrarotto
Journal:  Curr Treat Options Oncol       Date:  2022-07-19

3.  The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype.

Authors:  Maximilian Linxweiler; Fengshen Kuo; Nora Katabi; Mark Lee; Zaineb Nadeem; Martin G Dalin; Vladimir Makarov; Diego Chowell; Snjezana Dogan; Ian Ganly; A Ari Hakimi; Richard J Wong; Nadeem Riaz; Alan L Ho; Timothy A Chan; Luc G T Morris
Journal:  Clin Cancer Res       Date:  2020-02-14       Impact factor: 12.531

4.  Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer.

Authors:  Yohei Masugi; Reiko Nishihara; Tsuyoshi Hamada; Mingyang Song; Annacarolina da Silva; Keisuke Kosumi; Mancang Gu; Yan Shi; Wanwan Li; Li Liu; Daniel Nevo; Kentaro Inamura; Yin Cao; Xiaoyun Liao; Katsuhiko Nosho; Andrew T Chan; Marios Giannakis; Adam J Bass; F Stephen Hodi; Gordon J Freeman; Scott J Rodig; Charles S Fuchs; Zhi Rong Qian; Jonathan A Nowak; Shuji Ogino
Journal:  Cancer Immunol Res       Date:  2017-10-16       Impact factor: 12.020

5.  Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.

Authors:  Alejandro Jiménez-Sánchez; Danish Memon; Stephane Pourpe; Harini Veeraraghavan; Yanyun Li; Hebert Alberto Vargas; Michael B Gill; Kay J Park; Oliver Zivanovic; Jason Konner; Jacob Ricca; Dmitriy Zamarin; Tyler Walther; Carol Aghajanian; Jedd D Wolchok; Evis Sala; Taha Merghoub; Alexandra Snyder; Martin L Miller
Journal:  Cell       Date:  2017-08-24       Impact factor: 41.582

6.  Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.

Authors:  Alejandro Jiménez-Sánchez; Paulina Cybulska; Katherine LaVigne Mager; Simon Koplev; Oliver Cast; Dominique-Laurent Couturier; Danish Memon; Pier Selenica; Ines Nikolovski; Yousef Mazaheri; Yonina Bykov; Felipe C Geyer; Geoff Macintyre; Lena Morrill Gavarró; Ruben M Drews; Michael B Gill; Anastasios D Papanastasiou; Ramon E Sosa; Robert A Soslow; Tyler Walther; Ronglai Shen; Dennis S Chi; Kay J Park; Travis Hollmann; Jorge S Reis-Filho; Florian Markowetz; Pedro Beltrao; Hebert Alberto Vargas; Dmitriy Zamarin; James D Brenton; Alexandra Snyder; Britta Weigelt; Evis Sala; Martin L Miller
Journal:  Nat Genet       Date:  2020-06-01       Impact factor: 38.330

7.  Myoepithelial Carcinoma Ex-Pleomorphic Adenoma: A Rare Pathology Misdiagnosed as Pleomorphic Adenoma; With a Novel TERT Promoter Mutation and High PD-L1 Expression.

Authors:  Christopher Cormier; Shweta Agarwal
Journal:  Head Neck Pathol       Date:  2021-06-14

8.  A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.

Authors:  Umair Mahmood; Andrew Bang; Yu-Hui Chen; Raymond H Mak; Jochen H Lorch; Glenn J Hanna; Mizuki Nishino; Claire Manuszak; Emily M Thrash; Mariano Severgnini; Matthew Sanborn; Vishwajith Sridharan; Danielle N Margalit; Roy B Tishler; Paul M Busse; Henning Willers; Harvey J Mamon; Hyung-Jin Yoo; Sara I Pai; Lori J Wirth; Robert I Haddad; Nicole G Chau; Jonathan D Schoenfeld
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-08-08       Impact factor: 8.013

9.  Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas.

Authors:  Christoph Arolt; Moritz Meyer; Alexander Quaas; Jens Peter Klussmann; Vanessa Ruesseler; Lisa Nachtsheim; Nora Wuerdemann; Thomas Dreyer; Stefan Gattenlöhner; Claus Wittekindt; Reinhard Buettner
Journal:  Cancer Immunol Immunother       Date:  2020-03-30       Impact factor: 6.968

10.  High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2.

Authors:  Yanyan Li; Zhaoduan Liang; Ye Tian; Wenxuan Cai; Zhiming Weng; Lin Chen; Huanling Zhang; Yifeng Bao; Hongjun Zheng; Sihai Zeng; Chunhua Bei; Yi Li
Journal:  Cancer Sci       Date:  2018-08-07       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.